Double-hit DLBCL: should we limit FISH testing?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Correlations Between Immunophenotypic Markers and Clinical Progression in Romanian Patients Diagnosed with Diffuse Large B-Cell Lymphoma.Medicina (Kaunas, Lithuania) · 2025
   Article
2. Altered pathways and targeted therapy in double hit lymphoma.Journal of hematology & oncology · 2022
   Review
3. Clinicopathological analysis of diffuse large B-cell lymphoma lacking surface immunoglobulin light chain restriction on flow cytometry.Journal of clinical and experimental hematopathology : JCEH · 2022
   Article
4. MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL).HemaSphere · 2019
   Article
5. High-grade B-Cell lymphoma withAutopsy & case reports
   Article

Corrections and comments

• Comment on
  High-grade B-cell lymphoma with2018

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as